Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome
Neuro-Oncology · 13.11.2026
DOI: 10.1093/neuonc/noag282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 13.11.2026. Verfasst von Roberta Rudà und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy.
Abstract (Originalsprache)
Background
The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. Patients and Methods We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models.
Results
With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of − 12.2% at cycle 6, −27.8% at cycle 12, and −55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event.
Conclusions
Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy.
- Neurosurgical Oncological Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
- Neurosurgical Oncological Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio and Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
- Division of Neurosurgery, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy.
- Division of Neuroradiology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, Turin, Italy.
- Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
Zitieren
APA
Rudà, R., Bruno, F., Pronello, E., Pellerino, A., Scalvini, F., Conti Nibali, M., Rossi, M., Sciortino, T., Gay, L., Gallotti, A. L., Cofano, F., Morana, G., Nocera, G., Castellano, A., Falini, A., Ponzetto, F., Leoni, L., Melis, A., Mengozzi, G., …, & Soffietti, R. (2026). Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag282
Vancouver
Rudà R, Bruno F, Pronello E, Pellerino A, Scalvini F, Conti Nibali M, et al. Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag282
BibTeX
@article{Rud2026,
author = {Rudà, Roberta and Bruno, Francesco and Pronello, Edoardo and Pellerino, Alessia and Scalvini, Francesca and Conti Nibali, Marco and Rossi, Marco and Sciortino, Tommaso and Gay, Lorenzo and Gallotti, Alberto Luigi and Cofano, Fabio and Morana, Giovanni and Nocera, Gianluca and Castellano, Antonella and Falini, Andrea and Ponzetto, Federico and Leoni, Laura and Melis, Alessia and Mengozzi, Giulio and Ricci, Alessia Andrea and Bertero, Luca and Cassoni, Paola and Garbossa, Diego and Bello, Lorenzo and Soffietti, Riccardo},
title = {Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag282}
}
EUVIMED